Abstract

Integra Lifesciences will report fiscal second-quarter results on July 29, 2026, Pre-MKt, with investors watching revenue, margins, and adjusted EPS amid management’s guidance cadence and ongoing execution in surgical solutions and tissue technologies.

Market Forecast

Consensus points to revenue of 418.65 million US dollars for the current quarter, with expected year-over-year growth of 5.97%, EBIT of 61.03 million US dollars with 12.35% growth, and EPS of 0.48 with 12.00% growth; year-over-year growth rates are derived from decimal ratios and presented as percentages. While specific gross and net margin forecasts are limited, the company’s last disclosed gross margin baseline of 58.28% and the prior quarter’s profitability imply a focus on sustaining mid-to-high 50% gross margins and improving net margin alongside EPS expansion of 7.42% year over year. The main business profile continues to emphasize Surgical Specialties Solutions and Tissue Technologies, with Surgical Specialties Solutions likely to carry near-term growth and mix, and Tissue Technologies expected to contribute steady volume.

The most promising segment is Surgical Specialties Solutions, carrying 283.14 million US dollars in the prior quarter’s revenue, which set the scale for current-quarter expansion; the segment’s growth potential is tied to procedure volumes and product cadence, while Tissue Technologies delivered 108.78 million US dollars, offering a consistent base for balanced growth.

Last Quarter Review

In the prior quarter, Integra Lifesciences reported revenue of 391.92 million US dollars, a gross profit margin of 58.28%, GAAP net profit attributable to shareholders of -4.62 million US dollars with a net margin of -1.18%, and adjusted EPS of 0.54, with year-over-year growth of 31.71%. A notable highlight was the outperformance versus consensus across revenue and adjusted EPS, with EBIT of 65.19 million US dollars and a positive year-over-year expansion of 21.58%. Main business contribution was led by Surgical Specialties Solutions at 283.14 million US dollars and Tissue Technologies at 108.78 million US dollars, with the former representing approximately 72.24% of sales and underpinning overall stability; year-over-year segment growth rates were not disclosed.

Current Quarter Outlook

Main Business: Surgical Specialties Solutions

Surgical Specialties Solutions remains the company’s revenue anchor, historically accounting for more than two-thirds of quarterly sales. With procedure activity normalizing and hospital capital and utilization trends improving, this segment’s throughput provides leverage to both revenue and gross margin given scale and product mix. The current-quarter forecast implies that execution in core surgical franchises should help maintain mid-to-high 50% gross margins, with incremental operating leverage aiding EBIT growth of 12.35% year over year. Product availability and salesforce productivity will be key operational drivers, while pricing discipline and mix management can help offset inflationary headwinds in components and logistics.

Most Promising Business: Execution-Driven Expansion in Surgical Portfolio

The growth case this quarter is framed by Surgical Specialties Solutions’ base of 283.14 million US dollars last quarter and expected procedure volume resilience. With management previously emphasizing cost controls and productivity, the translation to EPS is reflected in the 12.00% year-over-year EPS growth forecast. Consistent conversion from revenue to EBIT, supported by normalized inventory and stable manufacturing yields, should contribute to net margin repair from last quarter’s GAAP loss. If product cadence and hospital demand hold, revenue growth around 5.97% year over year could pair with improving margins to drive a stronger operating profile.

Stock Price Drivers: Margins, EPS Delivery, and Mix

The stock is likely to react to the interplay between revenue growth and profitability consistency, particularly the relationship between gross margin trajectory and EBIT delivery. After a GAAP net loss last quarter, investors will focus on signs of net margin normalization and the durability of adjusted EPS expansion; delivery near or above the 0.48 EPS forecast would reinforce confidence in execution. Mix between Surgical Specialties Solutions and Tissue Technologies will influence gross margin, and any update to pricing, supply chain stability, or cost savings run-rate can reset expectations. Guidance quality for the balance of the fiscal year will also be pivotal, as management commentary can shape the valuation anchor through operating margin targets and capital allocation priorities.

Analyst Opinions

Across recent analyst commentaries and rating actions, the balance of views leans bullish, with a majority citing improving execution, procedure volume stability, and the potential for continued adjusted EPS progress as catalysts into the upcoming print. Well-followed sell-side coverage emphasizes the visibility implied by the revenue estimate of 418.65 million US dollars and mid-50% gross margin baseline, arguing that modest outperformance on operating leverage could support upside to EBIT and EPS. Analysts also highlight Surgical Specialties Solutions as the strength underpinning the outlook, expecting stable demand and disciplined cost control to translate into better year-over-year comps; while risks around supply chain and price remain, the prevailing opinion anticipates a constructive trajectory for margins and earnings.